The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with Т790М mutation to anti-EGFR drugs in non-small cell lung cancer

Abstract

Understanding the mechanisms of acquired resistance to tyrosine kinase inhibitors is important for clinicians from the perspective of the possibility of forming more effective options for the second and subsequent treatment of non-small cell lung cancer. The prospects of treatment strategies for patients with non-small cell lung cancer featuring the acquired resistance to tyrosine kinase inhibitors, not associated with the Т790М mutation, are quite vast from a scientific point of view, but in routine clinical practice they are not yet available in full. This article describes the current understanding of the mechanisms of acquired resistance to tyrosine kinase inhibitors not associated with the mutation of T790M, the evolution of views concerning the treatment of non-small cell lung cancer, progressing in the course of the treatment by this group of drugs. The possibilities of effective use of targeted therapy and various combinations of antitumor agents in such cases are also considered. Taking into account the diversity of unresolved issues and directions of further scientific research, we should not forget about the available research results and the ability to use the described options in routine clinical practice in a proper way.

Keywords

• acquired resistance
• epidermal growth factor receptor
• non-small cell lung cancer
• tyrosine kinase inhibitors of egfr
• egfr-activating mutations